135 related articles for article (PubMed ID: 9163593)
1. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Killick SB; Marsh JC; Hale G; Waldmann H; Kelly SJ; Gordon-Smith EC
Br J Haematol; 1997 May; 97(2):306-8. PubMed ID: 9163593
[TBL] [Abstract][Full Text] [Related]
2. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
3. CAMPATH-1H in the treatment of autoimmune cytopenias.
Marsh JC; Gordon-Smith EC
Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
[TBL] [Abstract][Full Text] [Related]
4. Campath-1H therapy in refractory ocular inflammatory disease.
Dick AD; Meyer P; James T; Forrester JV; Hale G; Waldmann H; Isaacs JD
Br J Ophthalmol; 2000 Jan; 84(1):107-9. PubMed ID: 10611109
[TBL] [Abstract][Full Text] [Related]
5. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
8. Remission induced by Campath-1H for thymoma-associated agranulocytosis.
Alvares CL; Svasti-Salee D; Rowley M; Gordon-Smith EC; Marsh JC
Ann Hematol; 2004 Jun; 83(6):398-400. PubMed ID: 14689236
[TBL] [Abstract][Full Text] [Related]
9. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
10. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.
Weinblatt ME; Maddison PJ; Bulpitt KJ; Hazleman BL; Urowitz MB; Sturrock RD; Coblyn JS; Maier AL; Spreen WR; Manna VK
Arthritis Rheum; 1995 Nov; 38(11):1589-94. PubMed ID: 7488279
[TBL] [Abstract][Full Text] [Related]
11. In vivo 'purging' of residual disease in CLL with Campath-1H.
Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab (Campath-1H): a systematic review in organ transplantation.
Morris PJ; Russell NK
Transplantation; 2006 May; 81(10):1361-7. PubMed ID: 16732169
[TBL] [Abstract][Full Text] [Related]
13. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
14. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
Isaacs JD; Manna VK; Rapson N; Bulpitt KJ; Hazleman BL; Matteson EL; St Clair EW; Schnitzer TJ; Johnston JM
Br J Rheumatol; 1996 Mar; 35(3):231-40. PubMed ID: 8620297
[TBL] [Abstract][Full Text] [Related]
15. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
16. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
17. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
Hirst C; Raasch S; Llewelyn G; Robertson N
J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):800-2. PubMed ID: 16705208
[No Abstract] [Full Text] [Related]
18. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
[No Abstract] [Full Text] [Related]
19. Induction therapy for adult small bowel transplant with Campath-1H.
Nishida S; Levi D; Kato T; Madariaga J; Nery J; Tzakis A
Transplant Proc; 2002 Aug; 34(5):1889-91. PubMed ID: 12176616
[No Abstract] [Full Text] [Related]
20. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
